Compare LMND & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | IRTC |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 1282 | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 2016 |
| Metric | LMND | IRTC |
|---|---|---|
| Price | $51.46 | $108.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $70.86 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.3M | 490.9K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $65.20 | $19.60 |
| Revenue Next Year | $33.31 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $35.70 | $101.75 |
| 52 Week High | $99.90 | $210.01 |
| Indicator | LMND | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 40.23 |
| Support Level | $48.81 | N/A |
| Resistance Level | $58.53 | $126.41 |
| Average True Range (ATR) | 3.12 | 6.18 |
| MACD | -0.28 | -0.69 |
| Stochastic Oscillator | 6.02 | 27.27 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.